Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

2,243 bytes added, 28 September
m
no edit summary
===Regimen variant #1, 7 days {{#subobject:bad5a2|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (C)
|1. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
===Regimen variant #2, 5-2-2 {{#subobject:38dc01|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[https://doi.org/10.1038/leu.2014.85 Drummond et al. 2014]
|2010
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (C)
|1. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
===References===
# Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NC, Hartley S, Kell J, Szubert A, Cockerill PN, Bowen DT. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. 2014 Jul;28(7):1570-2. Epub 2014 Feb 26. [https://doi.org/10.1038/leu.2014.85 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/24569776 PubMed]ISRCTN21428905# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [https://doi.org/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28486043 PubMed]NCT01522976
==Azacitidine & Lenalidomide {{#subobject:92571f|Regimen=1}}==
===Regimen variant #1, 7 days of azacitidine {{#subobject:dbee1c|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
===Regimen variant #2, 5-2-2 azacitidine {{#subobject:8be395|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
===References===
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [https://doi.org/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28486043 PubMed]NCT01522976
==Azacitidine & Vorinostat {{#subobject:a816bd|Regimen=1}}==
===Regimen variant #1, 7 days of azacitidine {{#subobject:68c3a6|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
===Regimen variant #2, 5-2-2 azacitidine {{#subobject:fbb1d5|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 2520%"|Study!style="width: 2520%"|Years of enrollment!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]!style="width: 2520%"|Comparator!style="width: 2520%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|rowspan=2|[https://doi.org/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2|2012-2014
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
===References===
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [https://doi.org/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28486043 PubMed]NCT01522976
==Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}==
===References===
# Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08235.x/full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20497178 PubMed] content property of [http://hemonc.org HemOnc.org]
 
==Decitabine and cedazuridine monotherapy {{#subobject:c98ugac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5ocu131c|Variant=1}}===
{| class="wikitable sortable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 20%"|Study
!style="width: 20%"|Years of enrollment
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7414597/ Garcia-Manero et al. 2020 (ASTX727-01-B)]
|2014-NR
| style="background-color:#91cf61" |Randomized Phase II, <20 pts in this subgroup (E-RT-switch-ic)
|[[#Decitabine_monotherapy|Decitabine]]
| style="background-color:#d3d3d3" |Not reported (*)
|-
|}
''Note: this was a randomized crossover trial examining PK/PD, and was not designed to compare efficacy.''
====Chemotherapy====
*[[Decitabine and cedazuridine (Inqovi)]] 35/100 mg PO once per day on days 1 to 5
 
'''28-day cycles'''
===References===
#'''ASTX727-01-B:''' Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 Aug 6;136(6):674-683. [https://doi.org/10.1182/blood.2019004143 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7414597/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/32285126 PubMed] NCT02103478
[[Category:Chronic myelomonocytic leukemia regimens]]
[[Category:Disease-specific pages]]
[[Category:Myeloproliferative neoplasms]]
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu